# IN8BIO, Inc.: financial statements, quarterly

INAB · Nasdaq · CIK 1740279 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/inab.md) · [Financials](/companies/inab/financials.md) · [Filings](/companies/inab/filings.md) · [Insiders](/companies/inab/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/inab/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | [3,786](/filings/0000950170-24-125537.md) | [4,522 d](/filings/0000950170-25-038738.md) | [4,903](/filings/0000950170-25-065609.md) | [5,156](/filings/0000950170-25-105028.md) | [3,309](/filings/0001193125-25-269447.md) | [3,594 d](/filings/0001193125-26-104181.md) | [2,972](/filings/0001193125-26-212135.md) | [2,487](/filings/0001193125-26-338012.md) | [2,104](/filings/0001193125-25-269447.md) | [2,648 d](/filings/0001193125-26-104181.md) | [2,613](/filings/0001193125-26-212135.md) | [2,493](/filings/0001193125-26-338012.md) |
| Operating income | $k | [(7,169)](/filings/0000950170-24-125537.md) | [(7,598) d](/filings/0000950170-25-038738.md) | [(8,562)](/filings/0000950170-25-065609.md) | [(8,629)](/filings/0000950170-25-105028.md) | [(7,086)](/filings/0001193125-25-269447.md) | [(6,160) d](/filings/0001193125-26-104181.md) | [(5,550)](/filings/0001193125-26-212135.md) | [(5,094)](/filings/0001193125-26-338012.md) | [(3,854)](/filings/0001193125-25-269447.md) | [(4,942) d](/filings/0001193125-26-104181.md) | [(5,090)](/filings/0001193125-26-212135.md) | [(4,781)](/filings/0001193125-26-338012.md) |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(7,169)](/filings/0000950170-24-125537.md) | [(7,598) d](/filings/0000950170-25-038738.md) | [(8,562)](/filings/0001193125-25-269447.md) | [(8,629)](/filings/0001193125-25-269447.md) | [(7,086)](/filings/0001193125-25-269447.md) | [(6,160) d](/filings/0001193125-26-104181.md) | [(5,550)](/filings/0001193125-26-338012.md) | [(5,094)](/filings/0001193125-26-338012.md) | [(3,854)](/filings/0001193125-25-269447.md) | [(4,942) d](/filings/0001193125-26-104181.md) | [(5,090)](/filings/0001193125-26-338012.md) | [(4,781)](/filings/0001193125-26-338012.md) |
| Diluted EPS | $ per share | [(0.23)](/filings/0000950170-24-125537.md) | not reported | [(0.20)](/filings/0000950170-25-065609.md) | [(5.51)](/filings/0000950170-25-105028.md) | [(4.49)](/filings/0001193125-25-269447.md) | not reported | [(2.16)](/filings/0001193125-26-212135.md) | [(1.24)](/filings/0001193125-26-338012.md) | [(0.85)](/filings/0001193125-25-269447.md) | not reported | [(0.26)](/filings/0001193125-26-212135.md) | [(0.25)](/filings/0001193125-26-338012.md) |
| Basic EPS | $ per share | [(0.23)](/filings/0000950170-24-125537.md) | not reported | [(0.20)](/filings/0000950170-25-065609.md) | [(5.51)](/filings/0000950170-25-105028.md) | [(4.49)](/filings/0001193125-25-269447.md) | not reported | [(2.16)](/filings/0001193125-26-212135.md) | [(1.24)](/filings/0001193125-26-338012.md) | [(0.85)](/filings/0001193125-25-269447.md) | not reported | [(0.26)](/filings/0001193125-26-212135.md) | [(0.25)](/filings/0001193125-26-338012.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [12.9](/filings/0000950170-24-125537.md) | [21.3](/filings/0000950170-25-038738.md) | [13.0](/filings/0000950170-25-065609.md) | [10.2](/filings/0000950170-25-105028.md) | [4.0](/filings/0001193125-25-269447.md) | [11.1](/filings/0001193125-26-104181.md) | [11.9](/filings/0001193125-26-212135.md) | [13.2](/filings/0001193125-26-338012.md) | [10.7](/filings/0001193125-25-269447.md) | [27.1](/filings/0001193125-26-338012.md) | [21.9](/filings/0001193125-26-212135.md) | [18.0](/filings/0001193125-26-338012.md) |
| Current assets | $m | [16.5](/filings/0000950170-23-062018.md) | [24.6](/filings/0000950170-25-038738.md) | not reported | [12.7](/filings/0000950170-24-093943.md) | [6.7](/filings/0000950170-24-125537.md) | [12.6](/filings/0001193125-26-104181.md) | [12.7](/filings/0000950170-25-065609.md) | [13.7](/filings/0000950170-25-105028.md) | [11.8](/filings/0001193125-25-269447.md) | [27.9](/filings/0001193125-26-338012.md) | [22.7](/filings/0001193125-26-212135.md) | [18.5](/filings/0001193125-26-338012.md) |
| Total assets | $m | [26.2](/filings/0000950170-23-062018.md) | [33.7](/filings/0000950170-25-038738.md) | not reported | [22.5](/filings/0000950170-24-093943.md) | [16.0](/filings/0000950170-24-125537.md) | [20.9](/filings/0001193125-26-104181.md) | [19.9](/filings/0000950170-25-065609.md) | [19.4](/filings/0000950170-25-105028.md) | [16.8](/filings/0001193125-25-269447.md) | [32.3](/filings/0001193125-26-338012.md) | [26.3](/filings/0001193125-26-212135.md) | [21.7](/filings/0001193125-26-338012.md) |
| Current liabilities | $m | [4.7](/filings/0000950170-23-062018.md) | [5.4](/filings/0000950170-25-038738.md) | not reported | [4.8](/filings/0000950170-24-093943.md) | [3.6](/filings/0000950170-24-125537.md) | [3.1](/filings/0001193125-26-104181.md) | [3.0](/filings/0000950170-25-065609.md) | [2.0](/filings/0000950170-25-105028.md) | [1.7](/filings/0001193125-25-269447.md) | [3.2](/filings/0001193125-26-338012.md) | [2.2](/filings/0001193125-26-212135.md) | [2.3](/filings/0001193125-26-338012.md) |
| Total liabilities | $m | [8.5](/filings/0000950170-23-062018.md) | [8.8](/filings/0000950170-25-038738.md) | not reported | [8.9](/filings/0000950170-24-093943.md) | [7.4](/filings/0000950170-24-125537.md) | [6.5](/filings/0001193125-26-104181.md) | [6.0](/filings/0000950170-25-065609.md) | [4.1](/filings/0000950170-25-105028.md) | [3.6](/filings/0001193125-25-269447.md) | [4.7](/filings/0001193125-26-338012.md) | [3.5](/filings/0001193125-26-212135.md) | [3.4](/filings/0001193125-26-338012.md) |
| Shareholders' equity | $m | [17.8](/filings/0000950170-24-125537.md) | [24.9](/filings/0001193125-26-104181.md) | [17.5](/filings/0001193125-25-269447.md) | [13.6](/filings/0001193125-25-269447.md) | [8.6](/filings/0001193125-25-269447.md) | [14.5](/filings/0001193125-26-338012.md) | [13.9](/filings/0001193125-26-338012.md) | [15.2](/filings/0001193125-26-338012.md) | [13.2](/filings/0001193125-25-269447.md) | [27.6](/filings/0001193125-26-338012.md) | [22.8](/filings/0001193125-26-338012.md) | [18.4](/filings/0001193125-26-338012.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(5,713) d](/filings/0000950170-24-125537.md) | [(4,850) d](/filings/0000950170-25-038738.md) | [(7,919)](/filings/0000950170-25-065609.md) | [(6,091) d](/filings/0000950170-25-105028.md) | [(6,111) d](/filings/0001193125-25-269447.md) | [(4,028) d](/filings/0001193125-26-104181.md) | [(3,122)](/filings/0001193125-26-212135.md) | [(3,927) d](/filings/0001193125-26-338012.md) | [(3,524) d](/filings/0001193125-25-269447.md) | [(2,139) d](/filings/0001193125-26-104181.md) | [(4,947)](/filings/0001193125-26-212135.md) | [(3,745) d](/filings/0001193125-26-338012.md) |
| Capital expenditure | $k | [0.0 d](/filings/0000950170-24-125537.md) | not reported | [50.0](/filings/0000950170-25-065609.md) | [21.0 d](/filings/0000950170-25-105028.md) | [0.0 d](/filings/0001193125-25-269447.md) | not reported | [0.0](/filings/0000950170-25-065609.md) | [0.0 d](/filings/0000950170-25-105028.md) | [0.0 d](/filings/0001193125-25-269447.md) | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [21.7](/filings/0000950170-23-062018.md) | [24.7](/filings/0000950170-24-056910.md) | [28.5](/filings/0000950170-24-093943.md) | [31.5](/filings/0000950170-24-125537.md) | [43.3](/filings/0000950170-25-065609.md) | [1.6](/filings/0000950170-25-105028.md) | [1.6](/filings/0001193125-25-269447.md) | [2.6](/filings/0001193125-26-212135.md) | [4.1](/filings/0001193125-26-338012.md) | [4.5](/filings/0001193125-25-269447.md) | [19.5](/filings/0001193125-26-212135.md) | [19.5](/filings/0001193125-26-338012.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 9,858,383 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338012.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.